Partnerships & Collaborations
We partner and collaborate with leading companies to
accelerate your projects and provide the best results
We partner and collaborate with leading companies to accelerate your projects and provide the best results
Partnerships &
Collaborations
We partner and collaborate with leading companies to accelerate your projects and provide the best results
Abzu
Abzu is a European AI company behind the QLattice ® —an explainable machine learning platform that accelerates siRNA therapeutic development. By applying interpretable models to large-scale datasets, Abzu helps design potent and selective siRNAs while minimizing sequence-dependent off-target effects, including miRNA-like interactions.
Alpha Preclinical
Provider of preclinical research services intended to address the rapid and expansive growth demand of the discovery preclinical research sector. The company offers IVIS imaging, colony management, iterative preclinical testing, surgical and in vitro laboratory services, thereby helping clients with their drug development and research programs.
Aurora Pharmaceuticals
Aurora is developing siRNA-based therapeutic eye drops crafted for safe yet potent modulation of conditions involving uveal melanocytes.
GenKardia
GenKardia is developing gene-based therapeutics for diastolic heart failure by targeting Titin, a key driver of cardiac stiffness. Their lead compound, GKA-100, reduces expression of the Titin N2B isoform, restoring heart flexibility through a mechanism inspired by how hibernating bears regulate cardiac elasticity.
SUNY Upstate – Lab of Audrey Bernstein
The Bernstein Lab at SUNY Upstate Medical University studies molecular drivers of blinding eye diseases, focusing on fibrotic and degenerative conditions in the cornea and anterior segment. Current work includes exploring protein aggregation, stress pathways, and the use of self-delivering siRNAs to modulate fibrosis and promote regeneration.
Sirnaomics
Sirnaomics is a clinical-stage biopharmaceutical company developing RNAi therapeutics for cancer and fibrotic diseases. Their siRNA candidates use proprietary polypeptide nanoparticle and GalNAc-conjugate delivery platforms to enable targeted, systemic delivery.
Vrata Therapeutics
Vrata Therapeutics is developing a cell-penetrating antibody capable of delivering nucleic acid cargo directly to the cytoplasm of cells in extrahepatic tissues. This approach bypasses the endosomal escape barrier, which otherwise limits the amount of nucleic acid therapeutic that reaches its intracellular site of action.